11-Deoxycorticosterone, Quantitative, Serum
11-Deoxycortocosterone (DOC) is an intermediate product during the biosynthesis of steroid hormone in the adrenal gland and gonads. It is produced from progesterone mostly in the zona glomerulosa of adrenal gland through the action of 21-α-hydroxylase. It is further converted to aldosterone (mineralocorticoid) by the action of 11-β-hydroxylase. This biosynthetic pathway is primarily controlled by the renin-angiotensin system in order to regulate electrolyte homeostasis and extracellular volume. Although it is an intermediate product, 11-Deoxycortocosterone exhibits a weak mineralocorticoid activity with negligible glucocorticoid activity. Therefore, the excessive level of DOC may result in clinical symptoms resembling hyperaldosteronism including increase sodium retention, hypertension, hypokalemic alkalosis, and suppression of the renin-angiotensin system.
Increase synthesis of DOC is characteristically seen in congenital adrenal hyperplasia (CAH) and deoxycorticosterone-producing tumors. CAH is caused by enzymatic defects in adrenal steroidogenesis. A deficiency of 11-β-hydroxylase is due to defect in CYP11B1 gene which causes impairment in the conversion of DOC to corticosterone ant the accumulation of DOC.
Females with the classic form of CAH due to 11-β-hydroxylase deficiency have external genitalia that do not look clearly male or female (ambiguous genitalia). However, the internal reproductive organs develop normally. Males and females with the classic form of this condition have early development of their secondary sexual characteristics such as growth of facial and pubic hair, deepening of the voice, appearance of acne, and onset of a growth spurt. The early growth spurt can prevent growth later in adolescence and lead to short stature in adulthood. In addition, approximately two-thirds of individuals with the classic form of CAH due to 11-β-hydroxylase deficiency have high blood pressure (hypertension). Hypertension typically develops within the first year of life.
- As an aid in diagnosis of suspected 11-hydroxylase deficiency
- Differential diagnosis of congenital adrenal hyperplasia due to 11-β-hydroxylase deficiency and 21-α-hydroxylase deficiency
- Useful in newborn screening of congenital adrenal hyperplasia
- Differential diagnosis of DOC-producing adrenocortical carcinoma
Increased in:
- Congenital adrenal hyperplasia due to deficiency of 11-β-hydroxylase (CYP11B1) and 17-α-hydroxylase (CYP17).
- DOC-producing adrenal adenoma
- Primary cortisol resistance syndrome
- Severe ACTH-dependent Cushing syndrome
- Pregnancy
- First week of life
Decreased in:
- Congenital adrenal hyperplasia due to 21-α-hydroxylase deficiency
- Congenital adrenal hyperplasia due to 3-β-steroid dehydrogenase deficiency
- Steroidogenic acute regulatory protein (StAR) deficiency
- Adrenal insufficiency (primary or secondary)
| Category | Subgroup | Reference Range (ng/dL) |
|---|---|---|
| Adults | Male | 3.5 – 11.5 |
| Female, follicular phase | 1.5 – 8.5 | |
| Female, luteal phase | 3.5 – 13.0 | |
| Pregnancy | 1st trimester | 5.0 – 25.0 |
| 2nd trimester | 10.0 – 75.0 | |
| 3rd trimester | 30.0 – 110.0 | |
| Children | < 1 year | 7.0 – 57.0 |
| 1–5 years | 4.0 – 49.0 | |
| 6–12 years | 9.0 – 34.0 |
Serum (SST), Serum (Red), Plasma EDTA (Lavender), Sodium Heparin (Green), Lithium Heparin (Green).
Stability
- Ambient: Unacceptable
- Refrigerated: 7 Days
- Frozen: 180 Days
- Eur J Pediatr. 1980 May;133(3):259-67. [PMID: 7389739]
- Endocr Pract. 2014;20:e171-5. [PMID: 25100384]
- J Clin Endocrinol Metab. 2006 Jun;91(6):2179-84. [PMID: 16551734]
- Stewart PM, Krone NP. The Adrenal Cortex. Williams Textbook of Endocrinology. 12th ed. Saunders Company: Philadelphia, PA; 2011. Page 479-544
- Demers LM. The Adrenal Cortex. Textbook of Clinical Chemistry and Molecular Diagnostics. 4th ed. 2006. Page 2003-52.
- Young WF. Endocrine Hypertension. Williams Textbook of Endocrinology. 12th ed. Saunders Company: Philadelphia, PA; 2011. Page 545-577.